Somewhat Positive Press Coverage Somewhat Unlikely to Affect Insys Therapeutics (INSY) Share Price
Media stories about Insys Therapeutics (NASDAQ:INSY) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Insys Therapeutics earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 45.9216962465275 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- INSYS Therapeutics, Inc. (INSY) stock moves -7.02% down in recent 30 days – Street Observer (press release) (streetobserver.com)
- INSYS Therapeutics Files New Drug Application (NDA) for Buprenorphine Sublingual Spray with FDA – Nasdaq (nasdaq.com)
- Off-Label Marketing Case Tossed (jdsupra.com)
- Insys Therapeutics (INSY) Presents At Cantor Fitzgerald Global Healthcare Conference – Slideshow (seekingalpha.com)
Several equities research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Insys Therapeutics from a “sell” rating to a “strong-buy” rating and set a $15.00 target price on the stock in a report on Wednesday, July 12th. TheStreet lowered shares of Insys Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, August 21st. Jefferies Group LLC reaffirmed a “buy” rating and issued a $14.00 target price on shares of Insys Therapeutics in a report on Friday, June 9th. Royal Bank Of Canada lowered their target price on shares of Insys Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, August 4th. Finally, BidaskClub lowered shares of Insys Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $13.25.
Insys Therapeutics (NASDAQ INSY) traded up 0.45% during midday trading on Friday, hitting $8.88. 367,170 shares of the stock traded hands. The stock’s market capitalization is $645.54 million. Insys Therapeutics has a 12-month low of $8.70 and a 12-month high of $15.06. The firm’s 50 day moving average is $9.45 and its 200-day moving average is $11.15.
Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.12. Insys Therapeutics had a negative return on equity of 3.02% and a negative net margin of 9.63%. The company had revenue of $42.60 million for the quarter, compared to analysts’ expectations of $36.90 million. During the same quarter last year, the business earned $0.13 earnings per share. Insys Therapeutics’s revenue was down 38.4% on a year-over-year basis. On average, analysts anticipate that Insys Therapeutics will post ($0.29) EPS for the current fiscal year.
In related news, CEO Saeed Motahari purchased 5,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average price of $8.92 per share, for a total transaction of $49,060.00. Following the completion of the transaction, the chief executive officer now owns 15,400 shares of the company’s stock, valued at $137,368. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder John N. Kapoor Trust Dated Sept purchased 17,500 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The stock was bought at an average price of $8.93 per share, for a total transaction of $156,275.00. Following the transaction, the insider now directly owns 31,982 shares of the company’s stock, valued at approximately $285,599.26. The disclosure for this purchase can be found here. 67.90% of the stock is currently owned by company insiders.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Stock Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related stocks with our FREE daily email newsletter.